CoChat

Lentiviral Vectors for Ocular Gene Therapy

Open access
Arsenijevic, Yvan, Berger, Adeline, Udry, Florian, Kostic, Corinne · 2022 · Pharmaceutics

The DOI matches its Crossref record; 206 of the 208 references it cites were found in a registry or an index.

Abstract

This review offers the basics of lentiviral vector technologies, their advantages and pitfalls, and an overview of their use in the field of ophthalmology. First, the description of the global challenges encountered to develop safe and efficient lentiviral recombinant vectors for clinical application is provided. The risks and the measures taken to minimize secondary effects as well as new strategies using these vectors are also discussed. This review then focuses on lentiviral vectors specifically designed for ocular therapy and goes over preclinical and clinical studies describing their safety and efficacy. A therapeutic approach using lentiviral vector-mediated gene therapy is currently being developed for many ocular diseases, e.g., aged-related macular degeneration, retinopathy of prematurity, inherited retinal dystrophies (Leber congenital amaurosis type 2, Stargardt disease, Usher syndrome), glaucoma, and corneal fibrosis or engraftment rejection. In summary, this review shows how lentiviral vectors offer an interesting alternative for gene therapy in all ocular compartments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics14081605

Cites

206 of 206 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Entry and integration of HIV-1. Structural and enzymatic HIV-1 genes are presented in gray boxes, HIV-1 regulatory factors in green, HIV-1 accessory factors in blue, and LTR in yellow. Corresponding proteins are represented with the same color code in a schematic HIV-1 particle. The different processes, from binding to the cell membrane to the integration of the provirus DNA into the host genome, are depicted with viral protein required at each step. The timing of uncoating of the capsid (CA) and the role of CA is still unclear, as discussed in a recent review [11]. The Gag gene codes for matrix proteins (MA), capsid proteins (CA), and nucleocapsid protein (NC). The Pol gene encodes for the reverse transcriptase (RT), the integrase (IN), and the protease (PRO).
Figure 1 Entry and integration of HIV-1. Structural and enzymatic HIV-1 genes are presented in gray boxes, HIV-1 regulatory factors in green, HIV-1 accessory factors in blue, and LTR in yellow. Corresponding proteins are represented with the same color code in a schematic HIV-1 particle. The different processes, from binding to the cell membrane to the integration of the provirus DNA into the host genome, are depicted with viral protein required at each step. The timing of uncoating of the capsid (CA) and the role of CA is still unclear, as discussed in a recent review [11]. The Gag gene codes for matrix proteins (MA), capsid proteins (CA), and nucleocapsid protein (NC). The Pol gene encodes for the reverse transcriptase (RT), the integrase (IN), and the protease (PRO).CC BY · PubMed Central
Figure 2 From lentivirus to 3rd generation lentiviral vector system. (A) Schematic representation of the natural HIV-1 genome. Structural and enzymatic HIV-1 genes are presented in gray boxes, HIV-1 regulatory factors in green, HIV-1 accessory factors in blue, and LTR in yellow. (B) Composition of the 4 plasmids co-transfected to generate LV; the envelope plasmid, the 2 packaging plasmids (expression of viral proteins), and the transgene plasmid (therapeutic cassette). Regulatory sequences used in the different plasmids generated for recombinant lentiviral production are in pink boxes, and the transgene in a red box. The curved arrow represents the start site of transcription. (C) Final genome of the recombinant lentiviral vector integrated into the host cell.
Figure 2 From lentivirus to 3rd generation lentiviral vector system. (A) Schematic representation of the natural HIV-1 genome. Structural and enzymatic HIV-1 genes are presented in gray boxes, HIV-1 regulatory factors in green, HIV-1 accessory factors in blue, and LTR in yellow. (B) Composition of the 4 plasmids co-transfected to generate LV; the envelope plasmid, the 2 packaging plasmids (expression of viral proteins), and the transgene plasmid (therapeutic cassette). Regulatory sequences used in the different plasmids generated for recombinant lentiviral production are in pink boxes, and the transgene in a red box. The curved arrow represents the start site of transcription. (C) Final genome of the recombinant lentiviral vector integrated into the host cell.CC BY · PubMed Central
Figure 3 Ocular administration routes. Lentiviral vectors are delivered in the eye using three main routes: intravitreal injection in the vitreous humor to target the ganglion cell layer, intracameral injection in the aqueous humor to target the trabecular meshwork, and subretinal injection between the neuroretina and the RPE to reach RPE and photoreceptors.
Figure 3 Ocular administration routes. Lentiviral vectors are delivered in the eye using three main routes: intravitreal injection in the vitreous humor to target the ganglion cell layer, intracameral injection in the aqueous humor to target the trabecular meshwork, and subretinal injection between the neuroretina and the RPE to reach RPE and photoreceptors.CC BY · PubMed Central
Figure 4 Diseases currently targeted by LV. LV treatments are evaluated for clinical application to treat several diseases of the anterior and posterior ocular compartments.
Figure 4 Diseases currently targeted by LV. LV treatments are evaluated for clinical application to treat several diseases of the anterior and posterior ocular compartments.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 206 references

Cited by

See all 47

Metadata

Authors
Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C.
Affiliations
  • Unit Retinal Degeneration and Regeneration, Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, 1004 Lausanne, Switzerland
  • Fondation Asile des Aveugles (CH)
  • Hôpital Ophtalmique Jules-Gonin (CH)
Corresponding author
Kostic, Corinne
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2022-07-31
Volume
14
Issue
8
Pages
1605
ISSN
1999-4923 (ISSN-L)
OpenAlex
W4289203946
Cited by
47
References
208
Citations by year
2026: 6 · 2025: 19 · 2024: 12 · 2023: 8 · 2022: 2
FWCI
1.58
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (publishedVersion, cc-by)
  • IRIS (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Fondation Asile des Aveugles (.)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
lentiviral vectors, ocular gene therapy, age-related macular degeneration, retinopathy of prematurity, inherited retinal disease, Stargardt disease, Usher syndrome, glaucoma, corneal fibrosis, preclinical and clinical studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lentiviral Vectors for Ocular Gene Therapy. https://app.cochat.ai/papers/10.3390/pharmaceutics14081605
The paper
Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C. (2022). Lentiviral Vectors for Ocular Gene Therapy. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14081605

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.